XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2022
Stockholders' Equity Note [Abstract]  
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:
 
Three Months Ended March 31,
(in thousands)20222021
Included in research and development expense$335 $40 
Included in selling, general and administrative expense817 228 
Total stock-based compensation expense$1,152 $268 
Schedule of Assumptions to Estimate Fair Value of Stock Option Awards
The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:
 
Three Months Ended March 31,
2022
Risk-free interest rate1.84 %
Dividend yield%
Expected volatility of Cardiff Oncology common stock106 %
Expected term6.0 years
Summary of Stock Option Activity and of Changes in Stock Options Outstanding
A summary of stock option activity and changes in stock options outstanding is presented below:
 
Total OptionsWeighted-Average
Exercise Price
Per Share
Intrinsic
Value
Balance outstanding, December 31, 20213,771,984 $7.13 $6,405,258 
Granted1,697,536 $3.19  
Canceled / Forfeited(1,109)$31.25  
Expired(800)$165.84  
Balance outstanding, March 31, 20225,467,611 $5.88 $65,189 
Exercisable at March 31, 20221,281,362 $8.83 $25,108 
Vested and expected to vest at March 31, 20225,331,850 $5.91 $61,800 
Summary of Warrant Activity and Changes in Warrants Outstanding
A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:
 
Total WarrantsWeighted-Average
Exercise Price
Per Share
Weighted-Average
Remaining Contractual
Term
Balance outstanding, December 31, 20214,490,159 $5.80 3.0 years
Balance outstanding, March 31, 20224,490,159 $5.80 2.7 years
Schedule of Preferred Stock
A summary of our Company's classes of preferred stock is presented below:
Shares outstanding
ClassPar valueShares designatedLiquidation preferenceAs of March 31,
2022
As of December 31,
2021
Series A Convertible Preferred Stock$0.001 277,100 $606,000 60,600 60,600 
Series B Convertible Preferred Stock$0.001 8,860 None— — 
Series C Convertible Preferred Stock$0.001 200,000 None— — 
Series D Convertible Preferred Stock$0.0001 154,670 None— — 
Series E Convertible Preferred Stock$0.001 865,824 None327,509 655,044